A Simple LC-MS/MS Method for Determination of Magnolol in Rat Blood and its Application in a Pharmacokinetic Study

Abstract

A simple LC-MS/MS method was developed for determination and pharmacokinetic study of magnolol in rat blood. Blood sample pretreatment involved a one-step extraction with methanol of 100 µL blood. The chromatographic separation was carried out on a Agilent Zobax SB C18 column with a mobile phase consisting of acetonitrile-0.2% formic acid (55:45, v/v) at a flow rate of 0.3 mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring via electro spray ionization source with positive mode. A high throughput was achieved with a run time of 4 min per sample. The standard curve for magnolol was linear (r > 0.999) over the concentration range of 2–1 000 ng/mL, with a lower limit of quantification of 2 ng/mL. The intra- and inter-day precision (relative standard deviation) values were not higher than 12% and the accuracy (relative error) was <5% at three quality control levels. This simple, fast and highly sensitive method was fully validated and successfully applied to a clinical pharmacokinetic study of magnolol in rats after oral administration.

Key words

magnolol - LC-MS/MS - pharmacokinetics

• References

• 1 Li MH, Kothandan G, Cho SJ et al. Magnolol Inhibits LPS-induced NF-κB/Rel Activation by Blocking p38 Kinase in Murine Macrophages. Korean J Physiol Pharmacol 2010; 14: 353-358
• 2 Yang SE, Hsieh MT, Tsai TH et al. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochemical Pharmacology 2002; 63: 1641-1651
• 3 Yang SE, Hsieh MT, Tsai TH et al. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. Br J Pharmacol 2003; 138: 193-201
• 4 Seo JU, Kim MH, Kim HM et al. Anticancer potential of magnolol for lung cancer treatment. Arch Pharm Res 2011; 34: 625-633
• 5 Hwang ES, Park KK. Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci Biotechnol Biochem 2010; 74: 961-967
• 6 Lin SY, Chang YT, Liu JD et al. Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Mol Carcinogen 2001; 32: 73-83
• 7 Lin SY, Liu JD, Chang HC et al. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 2002; 84: 532-544
• 8 Ikeda K, Nagase H. Magnolol has the ability to induce apoptosis in tumor cells. Biol Pharm Bull 2002; 25: 1546-1549
• 9 Lee J, Jung E, Park J et al. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 2005; 71: 338-343
• 10 Kotani A, Kojima S, Hakamata H et al. Determination of honokiol and magnolol by micro HPLC with electrochemical detection and its application to the distribution analysis in branches and leaves of Magnolia obovata. Chem Pharm Bull 2005; 53: 319-322
• 11 Wu YT, Lin LC, Tsai TH. Simultaneous determination of honokiol and magnolol in Magnolia officinalis by liquid chromatography with tandem mass spectrometric detection. Biomed Chromatogr 2006; 20: 1076-1081
• 12 Lin SP, Tsai SY, Lee Chao PD et al. Pharmacokinetics, Bioavailability, and Tissue Distribution of Magnolol Following Single and Repeated Dosing of Magnolol to Rats. Planta Med 2011; Jun 1 [Epub ahead of print]
• 13 US FDA . Guidance for Industry-Bioanalytical Method Validation. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. May 2001; Available from: http://www/fda.gov/cder/guidance/index.htm.